Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16

Journal of Virology

Volumn 85, Issue 14, 2011, Pages 7095-7107

  Davenport, Thaddeus M ^a,b   Friend, Della ^c   Ellingson, Katharine ^a   Xu, Hengyu ^c   Caldwell, Zachary ^a   Sellhorn, George ^a   Kraft, Zane ^a   Strong, Roland K ^c   Stamatatos, Leonidas ^a,b  

^a Seattle BioMed   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PG16; MONOCLONAL ANTIBODY PG9; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIGAND BINDING; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN QUATERNARY STRUCTURE;

ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CELL LINE; DNA PRIMERS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HUMANS; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; SOLUBILITY; SURFACE PLASMON RESONANCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79960391233     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00411-11     Document Type: Article

References (66)

1. Beddows, S., et al. 2007. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360:329-340.
2. Beddows, S., S. Lister, R. Cheingsong, C. Bruck, and J. Weber. 1999. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. J. Virol. 73:1740-1745.
3. Beddows, S., et al. 2005. Evaluating the immunogenicity of a disulfidestabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 79:8812-8827.
4. Berman, P. W., et al. 1992. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J. Virol. 66:4464-4469.
5. Binley, J. M., et al. 2002. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 76:2606-2616.
6. Blay, W. M., T. Kasprzyk, L. Misher, B. A. Richardson, and N. L. Haigwood. 2007. Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect the neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses. J. Virol. 81:13037-13049.
7. Blish, C. A., R. Nedellec, K. Mandaliya, D. E. Mosier, and J. Overbaugh. 2007. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 21: 693-702.
8. Blish, C. A., et al. 2010. Comparative immunogenicity of subtype a human immunodeficiency virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes. J. Virol. 84:2573-2584.
9. Changela, A., et al. 2011. Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. J. Virol. 85:2524-2535.
10. Cheng-Mayer, C., M. Quiroga, J. W. Tung, D. Dina, and J. A. Levy. 1990. Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J. Virol. 64:4390-4398.
11. Derby, N. R., et al. 2006. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J. Virol. 80:8745-8762.
12. Dey, A. K., K. B. David, M. Lu, and J. P. Moore. 2009. Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology 385:275-281.
13. Dey, B., et al. 2007. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J. Virol. 81:5579-5593.
14. Doores, K. J., et al. 2010. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc. Natl. Acad. Sci. U. S. A. 107: 13800-13805.
15. Doores, K. J., and D. R. Burton. 2010. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 84:10510-10521.
16. Doria-Rose, N. A., et al. 2010. Breadth of human immunodeficiency virusspecific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84:1631-1636.
17. Doria-Rose, N. A., et al. 2005. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J. Virol. 79:11214-11224.
18. Durocher, Y., S. Perret, and A. Kamen. 2002. High-level and high-throughput recombinant protein production by transient transfection of suspensiongrowing human 293-EBNA1 cells. Nucleic Acids Res. 30:E9.
19. Earl, P. L., and B. Moss. 1993. Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein. AIDS Res. Hum. Retroviruses 9:589-594.
20. Euler, Z., et al. 2010. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J. Infect. Dis. 201:1045-1053.
21. Forsell, M. N., et al. 2008. B cell recognition of the conserved HIV-1 coreceptor binding site is altered by endogenous primate CD4. PLoS Pathog. 4:e1000171.
22. Gilbert, P., et al. 2010. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J. Infect. Dis. 202:595-605.
23. Gorny, M. K., et al. 2005. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J. Virol. 79:5232-5237.
24. Gorny, M. K., J.-Y. Xu, S. Karwowska, A. Buchbinder, and S. Zolla-Pazner. 1993. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150:635-643.
25. Grundner, C., et al. 2005. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology 331:33-46.
26. Haigwood, N. L., et al. 1992. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J. Virol. 66:172-182.
27. Haigwood, N. L., et al. 1990. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res. Hum. Retroviruses 6:855-869.
28. Hanson, C. V. 1994. Measuring vaccine-induced HIV neutralization: report of a workshop. AIDS Res. Hum. Retroviruses 10:645-648.
29. Herrera, C., et al. 2005. The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology 338:154-172.
30. Herrera, C., et al. 2003. Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. J. Virol. 77:1084-1091.
31. Hoxie, J. A. 2010. Toward an antibody-based HIV-1 vaccine. Annu. Rev. Med. 61:135-152.
32. Hu, S. L., and L. Stamatatos. 2007. Prospects of HIV Env modification as an approach to HIV vaccine design. Curr. HIV Res. 5:507-513.
33. Keefer, M. C., et al. 1996. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses 12:683-693.
34. Klein, J. S., and P. J. Bjorkman. 2010. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog. 6:e1000908.
35. Kraft, Z., et al. 2008. Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses. J. Virol. 82:5912-5921.
36. Long, E. M., S. M. Rainwater, L. Lavreys, K. Mandaliya, and J. Overbaugh. 2002. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res. Hum. Retroviruses 18:567-576.
37. Mascola, J. R., and D. C. Montefiori. 2010. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28:413-444.
38. Mascola, J. R., et al. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:340-348.
39. Mikell, I., et al. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7:e1001251.
40. Mörner, A., et al. 2009. Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J. Virol. 83:540-551.
41. Nara, P. L., et al. 1988. Purified envelope glycoproteins from human immunodeficiency virus type I variants induce individual, type-specific neutralizing antibodies. J. Virol. 62:2622-2628.
42. Nkolola, J. P., et al. 2010. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J. Virol. 84:3270-3279.
43. Pancera, M., and R. Wyatt. 2005. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 332:145-156.
44. Pejchal, R., et al. 2010. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc. Natl. Acad. Sci. U. S. A. 107:11483-11488.
45. Phogat, S., and R. Wyatt. 2007. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr. Pharm. Des. 13:213-227.
46. Platt, E. J., K. Wehrly, S. E. Kuhmann, B. Chesebro, and D. Kabat. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72:2855-2864.
47. Poignard, P., et al. 2003. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 77:353-365.
48. Rich, R. L., and D. G. Myszka. 2008. Survey of the year 2007 commercial optical biosensor literature. J. Mol. Recognit. 21:355-400.
49. Robinson, J. E., et al. 2010. Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/ human immunodeficiency virus SHIVSF162P4. J. Virol. 84:3443-3453.
50. Sather, D. N., et al. 2009. Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
51. Saunders, C. J., et al. 2005. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J. Virol. 79:9069-9080.
52. Sellhorn, G., Z. Caldwell, C. Mineart, and L. Stamatatos. 2009. Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection. Vaccine 28:430-436.
53. Simek, M. D., et al. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:7337-7348.
54. Srivastava, I. K., et al. 2003. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J. Virol. 77:11244-11259.
55. Srivastava, I. K., et al. 2002. Purification and characterization of oligomeric envelope glycoprotein from a primary r5 subtype B human immunodeficiency virus. J. Virol. 76:2835-2847.
56. Srivastava, I. K., K. VanDorsten, L. Vojtech, S. W. Barnett, and L. Stamatatos. 2003. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J. Virol. 77:2310-2320.
57. Steimer, K. S., and N. L. Haigwood. 1992. Immunization of primates with native, recombinant HIV-SF2 gp120 generates broadly effective neutralizing antibodies directed to conformational epitopes. AIDS Res. Hum. Retroviruses 8:1391.
58. VanCott, T. C., et al. 1997. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficieny virus type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 71:4319-4330.
59. VanCott, T. C., et al. 1999. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. J. Virol. 73:4640-4650.
60. van Gils, M. J., Z. Euler, B. Schweighardt, T. Wrin, and H. Schuitemaker. 2009. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 23:2405-2414.
61. Walker, L. M., et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
62. Walker, L. M., et al. 2010. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6:1-14.
63. Wu, L., et al. 2006. Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope. Vaccine 24:4995-5002.
64. Wu, X., et al. 2011. Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies. J. Virol. 85:4578-4585.
65. Xu, H., et al. 2010. Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity. J. Virol. 84:1076-1088.
66. Yang, X., R. Wyatt, and J. Sodroski. 2001. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J. Virol. 75:1165-1171.